SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2013 / Cilt: 40 - Sayı: 3

The effect of topical cyclosporine A on tear film instability in patients with posterior blepharitis

Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi

ONUR ÇATAK
Ülkü ÇELİKER
Pages
446–448
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings should be further evaluated in large-scale.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to evaluate the efficacy of topical cyclosporine A (CsA) 0.05% (Restasis, Allergan Pharmaceuticals) in patients with posterior blepharitis.
📊
Key Findings & Data:Methods: The study included 15 patients with posterior blepharitis.
💡
Conclusion & Impact:These findings should be further evaluated in large-scale.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to evaluate the efficacy of topical cyclosporine A (CsA) 0.05% (Restasis, Allergan Pharmaceuticals) in patients with posterior blepharitis. Methods: The study included 15 patients with posterior blepharitis. Topical CsA 0.05% (Restasis, Allergan Pharmaceuticals) was applied twice a daily for 2 months. They were evaluated at baseline and after treatment for subjective symptoms and objective signs including tear breakup time (BUT), Schirmer scores, conjunctival hyperemia, tarsal telangiectasis and Meibomian gland inclusions. Results: Fifteen patients completed the study. At the 2-month visit, the patients showed improvement in ocular symptom including burning, itching, conjunctival hyperemia (p<0.05; p<0.001; p<0.001, respectively).Topical administration of CsA provided improvement in Schirmer scores (p<0.001) Conclusion: Topical CsA was inducing an improvement in the ocular symptoms. Topical CsA 0.05% may be helpful in the treatment of posterior blepharitis. These findings should be further evaluated in large-scale.

Özet

Amaç: Posterior blefaritli hastalarda topikal siklosporin A (CsA) tedavisinin etkinliğini değerlendirmek. Yöntemler: Posterior blefaritli 15 hasta çalışmaya dahil edildi. Hastalara 2 ay boyunca günde 2 kez topikal CsA %0.05 (Restasis, Allergan Pharmaceuticals) uygulandı. Hastalarda tedavi öncesi ve sonrası subjektif semptomlara ve gözyaşı kırılma zamanı (GKZ), Schirmer testi, konjonktival hiperemi, tarsal telenjiektazi ve meibomian bezi sekresyonuna bakıldı. Bulgular: 2 aylık takiplerde yanma, kaşıntı, konjonktival hiperemi semptomlarında azalma izlendi (Sırasıyla p<0,05; p<0,001; p<0,001). CsA tedavisi ile Schirmer testinde istatistiksel olarak anlamlı artış izlendi (p<0,001). Sonuç: Topikal CsA tedavisi ile klinik semptomlarda iyileşme izlenmiştir. Bu tedavi, posterior blefarit tedavisinde faydalı olabilir. Mevcut bulgular daha geniş çaplı çalışmalarla desteklenmelidir.

🔖

Cite This Article

ÇATAK, O., ÇELİKER, Ü. (2013). The effect of topical cyclosporine A on tear film instability in patients with posterior blepharitis. Dicle Tıp Dergisi, Cilt: 40 - Sayı: 3, 446–448. https://ajindex.com/articles/349024

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Thygeson P. Etiology and treatment of blepharitis; a study in military personnel. Arch Ophthalmol 1946;36:445-457
  2. Moore CP. Immunomodulating agents. In: Ocular Therapeutics. Elsevier Inc. 2004;725–737
  3. Sall K, Stevenson OD, Mundorf TK et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-639
  4. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis Am J Ophthalmol 1990;110:641-645
  5. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-1975
  6. Donshik P, Kulvin SM, Mckinley P, Skowron R. Treatment of chronic staphylococcal blepharoconjunctivitis with a new topical steroid anti-infective ophthalmic solution. Ann Ophthalmol 1983;15:162-167
  7. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 2003;29:96-99
  8. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 2006;46:105-122
  9. Salib G, McDonald M, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artifi cial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32:772–778
  10. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476-482
  11. Hom MM. The use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens 2006;32:109-111
  12. Hill JC. The use of systemic cyclosporin a in human corneal transplantation: a preliminary report. Documenta Ophthalmol 1986;62:337-344
  13. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-175
  14. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006;22:47-53.